Diagnosis and Treatment of Ovarian Cancer

Hematol Oncol Clin North Am. 2018 Dec;32(6):943-964. doi: 10.1016/j.hoc.2018.07.010.

Abstract

Epithelial ovarian cancer classically presents with vague persistent gastrointestinal, urologic, or nonacute abdominal/pelvic symptoms (bloating, early satiety, discomfort). Ultimately, a pelvic examination or imaging identifies an adnexal mass typically with accompanied advanced peritoneal dissemination. Management involves aggressive cytoreductive surgery in combination with platinum and taxane chemotherapy. Over the last 20 years, optimal resection and mode and timing of chemotherapy have evolved. The authors review the initial diagnosis and management and present the available data and recommendations to guide the decision tree of when to use neoadjuvant, intraperitoneal, HIPEC, dose-dense, and maintenance chemotherapy in the front-line treatment of epithelial ovarian cancer.

Keywords: Chemotherapy; Dose-dense; HIPEC; Intraperitoneal; Neoadjuvant; Ovarian cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bridged-Ring Compounds / therapeutic use
  • Carcinoma, Ovarian Epithelial* / diagnosis
  • Carcinoma, Ovarian Epithelial* / therapy
  • Combined Modality Therapy / methods
  • Cytoreduction Surgical Procedures / methods
  • Female
  • Humans
  • Hyperthermia, Induced / methods
  • Neoadjuvant Therapy / methods
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / therapy
  • Taxoids / therapeutic use

Substances

  • Bridged-Ring Compounds
  • Taxoids
  • taxane